These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 31371809)

  • 1. Insights into the success and failure of systemic therapy for hepatocellular carcinoma.
    Bruix J; da Fonseca LG; Reig M
    Nat Rev Gastroenterol Hepatol; 2019 Oct; 16(10):617-630. PubMed ID: 31371809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Zhu AX
    Expert Opin Investig Drugs; 2010 May; 19(5):663-72. PubMed ID: 20367287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.
    Hollebecque A; Malka D; Ferté C; Ducreux M; Boige V
    Eur J Cancer; 2015 Feb; 51(3):327-39. PubMed ID: 25559615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapies in hepatocellular carcinoma.
    Wörns MA; Weinmann A; Schuchmann M; Galle PR
    Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
    Brizzi MP; Pignataro D; Tampellini M; Scagliotti GV; Di Maio M
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1053-62. PubMed ID: 27548441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
    Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
    J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021.
    Brown ZJ; Hewitt DB; Pawlik TM
    Expert Opin Investig Drugs; 2022 Jul; 31(7):693-706. PubMed ID: 35580650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
    Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
    BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
    Kim R; Byrne MT; Tan A; Aucejo F
    Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
    Oikonomopoulos G; Aravind P; Sarker D
    Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.
    Tella SH; Kommalapati A; Mahipal A
    Chin Clin Oncol; 2021 Feb; 10(1):10. PubMed ID: 32434345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
    Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
    BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for hepatocellular carcinoma: current status and future perspectives.
    Ikeda M; Morizane C; Ueno M; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2018 Feb; 48(2):103-114. PubMed ID: 29253194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatocellular carcinoma].
    Kondo S; Ueno H; Morizane C; Okusaka T
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach.
    Villanueva A
    J Hepatol; 2013 Aug; 59(2):392-5. PubMed ID: 23548196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on clinical trials in the treatment of advanced hepatocellular carcinoma.
    Lee JK; Abou-Alfa GK
    J Clin Gastroenterol; 2013 Jul; 47 Suppl():S16-9. PubMed ID: 23751800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy in hepatocellular carcinoma.
    Wrzesinski SH; Taddei TH; Strazzabosco M
    Clin Liver Dis; 2011 May; 15(2):423-41, vii-x. PubMed ID: 21689622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New systemic agents for hepatocellular carcinoma: an update 2020.
    von Felden J
    Curr Opin Gastroenterol; 2020 May; 36(3):177-183. PubMed ID: 32101985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.